A Morpholino Oligomer Therapy Regime That Restores Mitochondrial Function and Prevents mdx Cardiomyopathy

Current clinical trials demonstrate Duchenne muscular dystrophy (DMD) patients receiving phosphorodiamidate morpholino oligomer (PMO) therapy exhibit improved ambulation and stable pulmonary function; however, cardiac abnormalities remain. Utilizing the same PMO chemistry as current clinical trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Viola, Helena M., Johnstone, Victoria P.A., Adams, Abbie M., Fletcher, Susan, Hool, Livia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059013/
https://www.ncbi.nlm.nih.gov/pubmed/30062225
http://dx.doi.org/10.1016/j.jacbts.2018.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059013/
https://www.ncbi.nlm.nih.gov/pubmed/30062225
http://dx.doi.org/10.1016/j.jacbts.2018.03.007

Ejemplares similares